Thursday, September 27, 2012
Northwest Biotherapeutics Inc., of Bethesda, Md., effected a 1-for-16 reverse split. The split is the first step toward a planned public offering of up to $25 million, and listing on the Nasdaq Capital Market.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.